As of the latest Form 4 filed Jul 10, 2026.
What Contineum Therapeutics, Inc. Class A Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 42 most recent filings for CTNM.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | 2026-07-09 | Lorrain Daniel S. Chief Scientific Officer | SSale | −25.00 | $16.00 | $400.00 | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-09 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +25.00 | $1.01 | $25.25 | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Lorrain Daniel S., Chief Scientific Officer | SSale | −1.01K | $16.00 | $16.2K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +1.01K | $1.01 | $1.03K | Yes (planned) | Form 4 ↗ |
| 2026-07-08 | 2026-07-08 | Stengone Carmine N. CEO and President | SSale | −2.50K | $16.00 | $40.0K | Yes (planned) | Form 4 ↗ |
| 2026-07-08 | 2026-07-08 | Stengone Carmine N., CEO and President | MExercise | +2.50K | $1.01 | $2.52K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Lorrain Daniel S. Chief Scientific Officer | SSale | −2.50K | $16.24 | $40.6K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Lorrain Daniel S., Chief Scientific Officer | SSale | −5.85K | $15.67 | $91.7K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +4.18K | $1.01 | $4.22K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Lorrain Daniel S., Chief Scientific Officer | SSale | −28.8K | $16.04 | $462K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +28.8K | $1.01 | $29.1K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Watkins Tim CMO & Head of Development | SSale | −10.8K | $16.02 | $174K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Watkins Tim, CMO & Head of Development | MExercise | +10.8K | $4.50 | $48.7K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Stengone Carmine N. CEO and President | SSale | −10.0K | $16.01 | $160K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Stengone Carmine N., CEO and President | MExercise | +2.50K | $1.26 | $3.15K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Stengone Carmine N., CEO and President | MExercise | +7.50K | $1.01 | $7.58K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Lorrain Daniel S. Chief Scientific Officer | SSale | −4.17K | $13.16 | $54.9K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Lorrain Daniel S. Chief Scientific Officer | SSale | −300.00 | $13.84 | $4.15K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Lorrain Daniel S., Chief Scientific Officer | SSale | −3.87K | $13.06 | $50.5K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-06 | Lorrain Daniel S. Chief Scientific Officer | SSale | −4.17K | $13.43 | $56.0K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | Lorrain Daniel S. Chief Scientific Officer | SSale | −4.17K | $15.01 | $62.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | Watkins Tim CMO & Head of Development | SSale | −3.61K | $15.02 | $54.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | Watkins Tim, CMO & Head of Development | MExercise | +3.61K | $4.50 | $16.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-25 | Stengone Carmine N. CEO and President | SSale | −2.70K | $16.02 | $43.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-25 | Stengone Carmine N., CEO and President | MExercise | +2.70K | $1.26 | $3.40K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-25 | Lorrain Daniel S. Chief Scientific Officer | SSale | −3.82K | $16.01 | $61.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-25 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +3.82K | $1.01 | $3.86K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Stengone Carmine N. CEO and President | SSale | −4.40K | $16.02 | $70.5K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Stengone Carmine N., CEO and President | MExercise | +4.40K | $1.26 | $5.54K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Lorrain Daniel S. Chief Scientific Officer | SSale | −4.30K | $16.03 | $68.9K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +4.30K | $1.01 | $4.34K | Yes (planned) | Form 4 ↗ |
| 2026-02-20 | 2026-02-19 | Lorrain Daniel S. Chief Scientific Officer | SSale | −100.00 | $16.00 | $1.60K | Yes (planned) | Form 4 ↗ |
| 2026-02-20 | 2026-02-19 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +100.00 | $1.01 | $101.00 | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Stengone Carmine N. CEO and President | SSale | −400.00 | $16.00 | $6.40K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Stengone Carmine N., CEO and President | MExercise | +400.00 | $1.26 | $504.00 | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Lorrain Daniel S. Chief Scientific Officer | SSale | −400.00 | $16.00 | $6.40K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Lorrain Daniel S., Chief Scientific Officer | MExercise | +400.00 | $1.01 | $404.00 | Yes (planned) | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Lorrain Daniel S. Chief Scientific Officer | SSale | −1.17K | $15.25 | $17.8K | Yes (planned) | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Lorrain Daniel S., Chief Scientific Officer | SSale | −3.00K | $14.82 | $44.5K | Yes (planned) | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Watkins Tim CMO & Head of Development | SSale | −811.00 | $14.48 | $11.7K | Yes (planned) | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Watkins Tim, CMO & Head of Development | SSale | −2.80K | $14.09 | $39.4K | Yes (planned) | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Watkins Tim, CMO & Head of Development | MExercise | +3.61K | $4.50 | $16.2K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CTNM’s full analysis or the market-wide insider trading feed. The tabs above jump to CTNM’s other SEC data.
Source: SEC Form 4 filings for CTNM, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.